INT107068

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2003
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 5
Total Number 8
Disease Relevance 1.81
Pain Relevance 2.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (BACE1) peptidase activity (BACE1) Golgi apparatus (BACE1)
endoplasmic reticulum (BACE1) enzyme binding (BACE1)
Anatomy Link Frequency
cleavage 4
BACE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
sodium channel 396 98.44 Very High Very High Very High
Eae 1 94.88 High High
cINOD 5 94.48 High High
Cholecystokinin 2 92.00 High High
Potency 1 75.68 Quite High
noradrenaline 1 63.80 Quite High
Serotonin 1 62.64 Quite High
Neurotransmitter 1 61.92 Quite High
Glutamate 1 59.92 Quite High
Enkephalin 2 25.00 Low Low
Disease Link Frequency Relevance Heat
Candida Infection 2 98.96 Very High Very High Very High
Alzheimer's Dementia 18 98.18 Very High Very High Very High
Disease 23 97.86 Very High Very High Very High
Immunization 1 95.44 Very High Very High Very High
INFLAMMATION 2 94.08 High High
Amyloid Plaque 1 90.32 High High
Dementia 2 85.84 High High
Vascular Dementia 1 84.60 Quite High
Hypertension 1 82.32 Quite High
Neuroblastoma 12 78.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The generation of the 2 kDa cleavage products was dramatically inhibited by the BACE1 inhibitor GL-189 (Figure 1A and 1B, lane #3).
Negative_regulation (inhibitor) of BACE1 in cleavage
1) Confidence 0.42 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC3022600 Disease Relevance 0 Pain Relevance 0.22
2 were expressed in CHO cells and crude membrane fractions prepared from those cells were incubated for 3 h at pH 4.5 with or without the BACE1 inhibitor GL-189.
Neg (without) Negative_regulation (inhibitor) of BACE1
2) Confidence 0.42 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC3022600 Disease Relevance 0 Pain Relevance 0.50
Identification of BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit

Background

Negative_regulation (Identification) of BACE1 in cleavage associated with sodium channel
3) Confidence 0.36 Published 2010 Journal Mol Neurodegener Section Title Doc Link PMC3022600 Disease Relevance 0.14 Pain Relevance 0.14
Mutations of the BACE1 cleavage site decrease processing in cell based models
Negative_regulation (decrease) of BACE1 in cleavage
4) Confidence 0.36 Published 2010 Journal Mol Neurodegener Section Body Doc Link PMC3022600 Disease Relevance 0.08 Pain Relevance 0.64
Other exciting approaches include modulation of A beta processing by inhibiting BACE1 or gamma-secretase or upregulating alpha-secretase; A beta peptide catabolism; inhibition of beta fibrillization; and reducing tau phosphorylation or inhibiting tau aggregation.
Negative_regulation (inhibiting) of BACE1 associated with eae
5) Confidence 0.27 Published 2008 Journal Bull. Acad. Natl. Med. Section Abstract Doc Link 18819689 Disease Relevance 0.88 Pain Relevance 0.25
In this regard, Y1 also efficiently inhibited Sap9p, a secreted aspartyl protease from the human pathogen, Candida albicans, which has specificity for basic residues similar to yapsin 1 and might provide the basis for the prevention or control of its virulence.
Negative_regulation (inhibited) of aspartyl protease associated with candida infection
6) Confidence 0.02 Published 2003 Journal J. Biol. Chem. Section Abstract Doc Link 12468548 Disease Relevance 0.10 Pain Relevance 0.03
The potent peptidic inhibitor, Y1, of the basic residue-specific yeast aspartyl protease, yapsin 1, was synthesized and characterized.
Negative_regulation (inhibitor) of aspartyl protease
7) Confidence 0.01 Published 2003 Journal J. Biol. Chem. Section Abstract Doc Link 12468548 Disease Relevance 0 Pain Relevance 0.05
This novel concept of manipulating the cleavage specificity of the gamma secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-beta(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease.
Negative_regulation (inhibition) of aspartyl-type protease in cleavage associated with alzheimer's dementia and disease
8) Confidence 0.01 Published 2008 Journal Curr Top Med Chem Section Abstract Doc Link 18220931 Disease Relevance 0.61 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox